ME Therapeutics Advances In Vivo CAR and Therapeutic mRNA STING Programs

VANCOUVER, British Columbia — ME Therapeutics Holdings Inc. (“ME Therapeutics” or the “Company”) (CSE: METX) (FSE: Q9T), a publicly listed biotechnology company developing novel cancer fighting drugs that reprogram and redirect immune cells to fight cancer, is pleased to provide a comprehensive update on its in vivo CD19/CD22-targeted chimeric antigen receptor (CAR) program, therapeutic mRNA […]